Compugen Ltd. (CGEN)
Stock Price:
$16.39 USD
0.06 (0.37%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $16.30 -0.09 (-0.55%) Aug 10, 5:55 PM
Key Info
| Market Cap |
1.36B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-27.34M |
| Shares Out |
82.86M |
| EPS (ttm) |
-0.37 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$16.39 |
| Previous Close |
$16.33 |
| Change ($) |
0.06 |
| Change (%) |
0.37% |
| Day's Open |
16.08 |
| Day's Range |
15.97 - 16.69 |
| Day's Volume |
1,050,736 |
| 52-Week Range |
3.22 - 17.85 |
More Stats
| Market Cap |
1.36B |
| Enterprise Value |
1.32B |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
82.86M |
| Float |
165.12M |
| EPS (basic) |
-0.43 |
| EPS (diluted) |
-0.37 |
| FCF / Share |
-0.44 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
6.42M |
| Short Ratio |
5.49 |
| Short % of Float |
11.05% |
| Beta |
2.76 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
10.53 |
| Revenue |
n/a |
| Operating Income |
-28.88M |
| Net Income |
-27.34M |
| Free Cash Flow |
-27.66M |
| Net Cash |
40.30M |
| Net Cash / Share |
0.49 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-17.73% |
| ROE |
-32.65% |
| ROIC |
-1,349.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (7)
| Buy |
7 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$20.14*
(22.88% upside)
Low
15.0
Current: $16.39
High
28.0
Target: 20.14
*Average 12-month price target from 7 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | 17.80 | - | 0.71 | 9.28 | 12.37 | 3.55 | 0.24 | - | 1.12 |
| Revenue Growth | - | - | - | -92.33% | -24.99% | 248.46% | 1366.53% | - | - | - |
| Gross Profit | - | 16.77 | - | 0.49 | 7.64 | 9.02 | 1.04 | 0.04 | - | 0.89 |
| Operating Income | -28.88 | -23.23 | -37.41 | -32.58 | -20.92 | -12.34 | -17.04 | -13.54 | -11.98 | -7.88 |
| Net Income | -27.34 | -22.60 | -37.07 | -31.51 | -20.16 | -11.09 | -14.08 | -13.63 | -12.00 | -7.20 |
| Shares Outstanding | 63.64 | 55.28 | 51.18 | 50.86 | 50.44 | 47.81 | 38.87 | 35.84 | 34.28 | 33.28 |
| Earnings Per Share | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.26 | -0.36 | -0.38 | -0.35 | -0.22 |
| Operating Cash Flow | -27.89 | -13.29 | -30.66 | -19.82 | -25.61 | -11.15 | -6.44 | -10.85 | -9.25 | -4.28 |
| Capital Expenditures | 0.23 | -0.16 | -0.39 | -2.60 | -3.12 | -1.90 | -0.33 | -1.01 | -0.10 | -0.02 |
| Free Cash Flow | -27.66 | -13.45 | -31.04 | -22.42 | -28.73 | -13.04 | -6.77 | -11.85 | -9.35 | -4.30 |
| Cash & Equivalents | 43.88 | 45.68 | 30.44 | 61.53 | 81.85 | 74.38 | 51.49 | 24.88 | 22.46 | 22.51 |
| Total Debt | 3.58 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 40.30 | 45.68 | 30.44 | 61.53 | 81.85 | 74.38 | 51.49 | 24.88 | 22.46 | 22.51 |
| Assets | 53.76 | 53.18 | 38.75 | 71.14 | 99.31 | 115 | 56.71 | 28.91 | 29.08 | 36.46 |
| Liabilities | 15.44 | 15.94 | 9.45 | 7.62 | 9.41 | 8.87 | 24.82 | 11.24 | 9.50 | 8.17 |
| Book Value | 38.32 | 37.24 | 29.30 | 63.52 | 89.90 | 106 | 31.89 | 17.67 | 19.58 | 28.29 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Compugen Ltd. |
| Country |
Israel |
| Employees |
61 |
| CEO |
Anat Cohen-Dayag |
Stock Information
| Ticker Symbol |
CGEN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CGEN |
| IPO Date |
August 11, 2000 |
Description
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; BAY 1905254, a therapeutic antibody targeting ILDR2, which is in Phase I clinical study in patients with solid tumors; and COM902, a therapeutic antibody targeting TIGIT. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics for antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.